Cardiology research institute, National Research Medical Center of the Russian Academy of Sciences
Tomsk, 634012, Russia
NCT Number: NCT03877731
The purpose of the study is to assess the role of mitral valve apparatus in the development of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the best surgical treatment modality to relieve outflow tract obstruction in such patients
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Tomsk, 634012, Russia
It is well-known that mitral valve plays an important role in the development of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. In order to further investigate this phenomenon, the following study aims to compare mitral valve geometry indices, as assessed by transthoracic echocardiography, two- and three-dimentional transesophageal echocardiography and mitral valve quantification analysis, and papillary musles' function, as assessed by 2D speckle tracking imaging, in patients with hypertrophic obstructive cardiomyopathy, patients with arterial hypertension and left ventricular hypertrophy and people without structural heart disease. This will provide information on the geometric characteristics of mitral valve that predispose to the development of obstruction. Futhermore, patients with hypertrophic obstructive cardiomyopathy that are eligible for the surgical relief of obstruction will be randomised into four groups according to the modality of intervention. These groups are as follows: 1) isolated extended septal myectomy; 2) extended septal myectomy + edge to edge mitral valve repair; 3) extended septal myectomy + posterior lealfet sliding plasty; 4) extended septal myectomy + secondary chordae transection. After surgery, said indices will be reassessed and the degree of outflow tract obstruction relief noted, in order to elicit which geometrical changes are produced by each type of intervention. Patients will be followed long-term, up to 5 years, in order to define whether the addition of the intervention on mitral valve helps abolish the residual gradient more effectively, and whether it translates into any survival benefit.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 years
patients' survival without hospital admissions due to the recurring sympthoms
Time frame: 5 years
left ventricular outflow tract gradient measured by continuous doppler from 5-chamber apical view
Time frame: 5 years
degree of mitral regurgitation assessed by color doppler, regurgitant volume measured using PISA method
Time frame: 5 years
papillary muscles' strain and strain rate assessed by 2D speckle tracking imaging
Time frame: 10 days
indices of mitral valve geometry assessed by 2D transthoracic and transesophageal echocardiography and mitral valve quantification analysis
Tomsk National Research Medical Center of the Russian Academy of Sciences
Other
Role of Mitral Valve in the Obstruction of Left Ventricular Outflow Tract in Patients With Hypertrophic Cardiomyopathy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04141891
Acute Coronary Syndrome, Aortic Stenosis, Subvalvular
La Jolla, California, United States
View Trial DetailsNCT04066777
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Aarhus N, Danmark, Denmark
View Trial DetailsNCT05850026
Aortic Stenosis, Subvalvular, Aortic Valve Disease
Milan, Italy
View Trial DetailsNCT05687487
Aortic Stenosis, Subvalvular, Aortic Valve Disease
View Trial Details